Here’s whether Cytokinetics Inc. (CYTK) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 39 — healthy momentum range; strong 1-year return of +47.6%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.38% over 10 days). Currently 10.8% off its 52-week high. Score: +2/7.
CYTK is holding above its long-term 200-day MA ($57.63) but has slipped below the 50-day MA ($63.75), pointing to short-term weakness in an otherwise intact trend. An RSI of 39.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +47.6% compares to +27.9% for SPY (beat the market by 19.7%).
$10,000 invested 1 year ago→ $14,760 today
vs. S&P 500 (SPY) — same period beat market by 19.7%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($57.63)
✗Above 50-day MA ($63.75)
✓RSI(14) neutral zone (30–70) — currently 39.3
✓Positive return (+47.6%)
!Within 10% of period high (−10.8%)
Period Range $63.35
$29.31$70.98
RSI (14) 39.3
0 · OversoldOverbought · 100
Key Metrics
Price$63.35
Period Return+47.6%
Period High$70.98
Period Low$29.31
Drawdown−10.8%
MA-50$63.75
MA-200$57.63
RSI (14)39.3
Avg Volume (30d)1.8M
vs. SPYbeat by 18.6%
Return Rank#397 of 1236
Trend Signals
Price is above the 200-day moving average ($57.63)